Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists and dual GLP-1/GIP agonists are associated with a high incidence of gastrointestinal adverse events.
- Common gastrointestinal issues include dyspepsia and symptoms resembling gastroparesis.
- Most gastrointestinal effects are transient, but a notable number of patients experience persistent intolerance.
- Persistent gastrointestinal symptoms can lead to misdiagnosis and unnecessary medical procedures.
- Current treatment guidelines provide limited support for managing symptoms in patients with these adverse events.
- There is a need for structured strategies to improve management, including risk stratification and tailored dose adjustments.
Simplified